Clinical trial NCT01023815: Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.
Official title: Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With Neoral Versus Corticosteroid Elimination).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: de Novo Kidney Transplant Recipients
Renal Transplantation
Keywords: Immunosuppression
renal transplantation
once-a-day regimen
steroid withdrawal
drug minimization
immunosuppression for prevention of acute rejections
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2009-12-02
Enrollment: 330
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will compare the following immunosuppressive regimens in recipients of kidney transplantation: A) everolimus, cyclosporine and steroids given once-a-day; B) everolimus and cyclosporine given twice a day with steroid withdrawal; C) everolimus, cyclosporine given twice a day and continuous steroids. The purpose of this study is to evaluate regimens A and B in comparison with the control group (group C) for efficacy, using as main endpoint the treatment failure rate, a composite endpoint including death, graft loss, BPAR and lost to follow-up between randomization and Month 12.


Eligibility criteria: Inclusion criteria:

* recipients of 1st or 2nd single kidney transplant
* donor age \>14 years
* females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at Baseline (Visit 2), and are required to practice an approved method of birth control for the duration of the study and for a period of 2 months following discontinuation of study medication
* patientswho are willing and able to participate in the study and from whom written informed consent has been obtained

Exclusion criteria:

Exclusion criteria at screening (pre-transplantation, Visit 1):

* recipients of kidney-pancreas transplant, double kidney or any other transplant
* recipients of a 2nd kidney transplant who lost the 1st for immunological reasons
* focal segmental glomerulosclerosis (FSGS), primary oxaluria or other diseases (as cause of end stage renal failure - ESRF) at high risk of rapid recurrence or requiring continuous corticosteroid treatment
* recipients of A-B-O incompatible transplants
* historical or current peak PRA of \>25% (current = 3 months)
* patients with already existing antibodies against the donor
* thrombocytopenia (platelets \<75,000/mm³), absolute neutrophil count of \<1,500/mm³, leucopenia (leucocytes \<2,500/mm³), or hemoglobin \<6 g/dL
* symptoms of significant somatic or mental illness. Inability to cooperate or communicate with the investigator, or to comply with the study requirements, or to give informed consent
* history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
* patients who are HIV positive or Hepatitis B surface antigen positive (HbsAg); HCV positive patients receiving interferon and/or ribavirin
* evidence of severe liver disease (incl. abnormal liver enzyme profile, i.e. AST, ALT or total bilirubin \>3 times UNL)
* evidence of drug or alcohol abuse
* body mass index (BMI) \>35
* patients who need to be treated with drugs known to strongly interact with CsA and/or everolimus (as detailed in Appendix 2 of the protocol) should be excluded, if according the investigator this interferes with the objectives of the study
* women of child-bearing potential, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method
* pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>5 mIU/mL)
* use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
* history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
* patients with severe active infections or any other medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)

Additional exclusion criteria post-transplantation (Visit 2):

• graft not perfused or with thrombosis of the main vessels, according to angioscintigraphy or echocolordoppler within 48 hours after the end of surgical procedure

To avoid any possible influence of the confounding factors on the results of this study additional exclusion criteria at randomization were (Visit 5, Month 3):

* unsatisfactory renal function (CrCl according Cockcroft and Gault\<40 mL/min)
* proteinuria ≥0.8 g/24 hrs
* steroid-resistant, humoral, moderate/severe (BANFF grade ≥II) biopsy proven acute rejections
* multiple (2 or more) biopsy proven or treated acute rejections or acute rejections leading to relevant loss of renal function
* acute rejection or impairment of renal function (increase of serum creatinine\>30%) in the month preceding randomization
* severe/uncontrollable adverse events with suspected relationship to everolimus (e.g. anemia, oral aphtosis, arthralgia) for the control of which the investigator has planned the withdrawal of everolimus
* severe infections requiring hospitalization in the two weeks preceding randomization
* poor compliance to prescribed treatments

  * Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Treatment Failure Rate
timeFrame: Between randomization (Month 3) and Month 12
Secondary outcomes:
measure: Changes in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12
timeFrame: Month 3 to Month 12
measure: Biopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 12
timeFrame: Month 3 to Month 12
measure: Number of Participants With Graft and Patient Survival After Randomization
timeFrame: Month 3 to Month 12
measure: Change in Estimated Creatine Clearance
timeFrame: M3, M12
measure: Change in Serum Creatinine
timeFrame: M3, M12
Other outcomes:
Locations:
city: Ancona
country: Italy
facility: Novartis Investigative Site
city: Bologna
country: Italy
facility: Novartis Investigative Site
city: Brescia
country: Italy
facility: Novartis Investigative Site
city: Cagliari
country: Italy
facility: Novartis Investigative Site
city: Catania
country: Italy
facility: Novartis Investigative Site
city: Coppito
country: Italy
facility: Novartis Investigative Site
city: Firenze
country: Italy
facility: Novartis Investigative Site
city: Genova
country: Italy
facility: Novartis Investigative Site
city: Milano
country: Italy
facility: Novartis Investigative Site
city: Modena
country: Italy
facility: Novartis Investigative Site
city: Napoli
country: Italy
facility: Novartis Investigative Site
city: Novara
country: Italy
facility: Novartis Investigative Site
city: Padova
country: Italy
facility: Novartis Investigative Site
city: Palermo
country: Italy
facility: Novartis Investigative Site
city: Parma
country: Italy
facility: Novartis Investigative Site
city: Perugia
country: Italy
facility: Novartis Investigative Site
city: Pisa
country: Italy
facility: Novarits Investigative Site
city: Roma
country: Italy
facility: Novartis Investigative Site
city: Rome
country: Italy
facility: Novartis Investigative Site
city: Salerno
country: Italy
facility: Novartis Investigative Site
city: Sassari
country: Italy
facility: Novartis Investigative Site
city: Siena
country: Italy
facility: Novartis Investigative Site
city: Torino
country: Italy
facility: Novartis Investigative Site
city: Treviso
country: Italy
facility: Novartis Investigative Site
city: Udine
country: Italy
facility: Novartis InvestigativeSite
city: Varese
country: Italy
facility: Novartis Investigative Site
city: Verona
country: Italy
facility: Novartis Investigative Site
city: Vicenza
country: Italy
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: